Clinical Trial Update: Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for oltipraz in reducing liver fat in non-alcoholic fatty liver disease (excluding cirrhosis) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Oltipraz (oltipraz)

Snippet

Sponsor: PharmaKing | Conditions: Non-Alcoholic Fatty Liver Disease | Phase 3 | Status: COMPLETED